Skip to Content

IMvigor130: Final overall survival (OS) analysis of atezolizumab with/without chemotherapy

IMvigor130 is a randomized phase III study investigating efficacy of first-line treatment with atezolizumab monotherapy versus atezolizumab in combination with chemotherapy versus chemotherapy monotherapy for advanced or metastatic urothelial carcinoma (mUC). Let Professor Aristotle Bamias present the exciting results presented at ASCO GU 2023 in this MEDtalk.

Aristotle Bamias

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top